Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...

Clesrovimab is an extended half-life RSV neutralizing antibody in development for all infants in their first RSV season and ...

Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing ...

Shawn Johnson shares daughter Drew Hazel, 4, and sons Jett James, 2, and Barrett 'Bear' Madison, 10 months, with her husband ...

The New Mexico Department of Health (NMDOH) is encouraging RSV immunizations and they are now available for pregnant people ...

Free shots that can protect babies from respiratory syncytial virus are being offered by some health-care providers in ...

There is also a vaccine called Abrysvo under the brand name and RSVpreF under the generic name, for pregnant women between 32 ...

WellSpan Ephrata Community Hospital is now offering respiratory syncytial virus immunizations to infants born at the hospital ...

Clesrovimab, formerly known as MK-1654, is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody.

Some Ontario doctors have started offering a free shot that can protect babies from respiratory syncytial virus while Quebec will begin its immunization program next month.

Merck's (MRK) monoclonal antibody clesrovimab shows cuts RSV infections by 60% in infants, with a strong safety profile. Read ...